サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1529374

糖尿病性腎症の世界市場-2024-2031

Global Diabetic Nephropathy Market - 2024-2031
出版日: | 発行: DataM Intelligence | ページ情報: 英文 185 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.72円
糖尿病性腎症の世界市場-2024-2031
出版日: 2024年08月06日
発行: DataM Intelligence
ページ情報: 英文 185 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

世界の糖尿病性腎症市場は、2023年に2億500万米ドルに達し、2031年には3億3,200万米ドルに達すると予測され、予測期間2024-2031年のCAGRは6.2%で成長する見込みです。

糖尿病性腎症は、糖尿病性腎臓病としても知られ、糖尿病患者に起こる慢性的な腎機能低下です。糖尿病性腎症は、慢性腎臓病および末期腎臓病の世界の主要原因です。

糖尿病性腎症は、高い血糖値が腎臓の血管やフィルターにダメージを与えるため、何年もかけてゆっくりと進行します。その結果、最終的には透析や腎移植を必要とする末期腎不全（ESRD）に至ることもあります。糖尿病、血圧、その他の危険因子の早期発見と管理は、糖尿病性腎臓病の発症や進行を予防したり遅らせたりするのに役立ちます。

市場力学：

促進要因

糖尿病人口の増加

世界の糖尿病性腎症市場の需要は、複数の要因によって牽引されています。1型および2型糖尿病の有病率の増加は、糖尿病性腎症市場の主要促進要因です。糖尿病は慢性腎臓病（CKD）の主要な原因の一つです。

国際DM連盟のAtlasは、2022年には5億3,700万人の成人（20～79歳）が糖尿病を患うと推定しており、この数は2030年には6億4,300万人、2045年には7億8,100万人に増加する可能性があるとしています。糖尿病患者の40％以上が腎臓関連の合併症を患っており、その多くが透析や腎移植を必要とする末期腎不全にまで進行しています。

さらに、啓発プログラムや糖尿病性腎症の治療開発における進行中の臨床試験といった政府の取り組みが、この市場の成長を促進すると思われます。例えば、2023年11月、ジッダの国際医療センターは、世界糖尿病デーに合わせて2日間の糖尿病啓発キャンペーンを開催しました。このキャンペーンは、世界で最も広く普及している病気の一つである糖尿病のさまざまなタイプについて一般の人々を教育し、その根本的な原因や糖尿病性足症、糖尿病性網膜症、糖尿病性腎症、歯の問題など、糖尿病に関連する可能性のある健康合併症を明らかにすることを通じて、糖尿病とそれに関連する健康リスクに対する認識を高めることに焦点を当てた。

また、バイエルは2023年2月、欧州委員会が欧州連合（EU）におけるケレンディア（一般名：ファインレノン）の添付文書延長を承認したと発表しました。FIGARO-DKD試験は、ステージ1～4のCKDおよびT2Dを有する幅広い患者集団において、ケレンディアが心血管イベントのリスクを低減することを実証しました。

阻害要因

高額な治療費、厳しい規制当局の承認、熟練した専門家の不足、認識・診断の不足、限られた治療選択肢の利用可能性などの要因が市場の阻害要因になると予想されます。

このレポートの詳細情報- サンプル請求

目次

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 糖尿病人口の増加
      • 診断技術の進歩
      • 臨床研究の増加と政府の取り組み
    • 抑制要因
      • 治療費の高騰
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • アンメットニーズ
  • PESTEL分析
  • 特許分析
  • SWOT分析

第6章 タイプ別

  • 1型糖尿病
  • 2型糖尿病

第7章 治療薬別

  • 薬剤クラス別
    • アンジオテンシン変換酵素（ACE）阻害薬
    • アンジオテンシン受容体拮抗薬（ARBs）
    • 利尿薬
    • カルシウム拮抗薬（CCBs）
    • レニン阻害薬
    • その他
  • 腎代替療法
    • 透析療法
    • 腎移植

第8章 エンドユーザー別

  • 病院およびクリニック
  • 外来手術センター
  • 在宅医療
  • その他

第9章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 中東・アフリカ

第10章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第11章 企業プロファイル

  • Novartis AG
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Merck & Co., Inc
  • Johnson & Johnson Services, Inc
  • Sanofi
  • AstraZeneca
  • AbbVie Inc
  • Eli Lilly and Company
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb
  • GSK plc

第12章 付録

目次
Product Code: PH2710

Overview

The global diabetic nephropathy market reached US$ 205 million in 2023 and is expected to reach US$ 332 million by 2031, growing at a CAGR of 6.2% during the forecast period 2024-2031.

Diabetic nephropathy, also known as diabetic kidney disease, is the chronic loss of kidney function that occurs in individuals with diabetes mellitus. It is the leading cause of chronic kidney disease and end-stage renal disease globally.

Diabetic nephropathy develops slowly over many years as high blood glucose levels damage the blood vessels and filters in the kidneys. This can eventually lead to kidney failure, also known as end-stage renal disease (ESRD), which requires dialysis or a kidney transplant. Early detection and management of diabetes, blood pressure, and other risk factors can help prevent or delay the onset and progression of diabetic kidney disease.

Market Dynamics: Drivers

Rising prevalence of diabetic population

The demand for the global diabetic nephropathy market is driven by multiple factors. The increasing prevalence of diabetes, both type 1 and type 2, is a major driver of the diabetic nephropathy market. Diabetes is one of the leading causes of chronic kidney disease (CKD).

The Atlas of the International DM Federation estimated that 537 million adults (20-79 years) will be living with DM in 2022, and this number could increase to 643 million by 2030 and 781 million by 2045. More than 40% of diabetic patients suffer from kidney-related complications, with many progressing to end-stage renal disease requiring dialysis or kidney transplantation.

Moreover, government initiatives such as awareness programs and ongoing clinical trials in the development of treatment for diabetic nephropathy would propel this market growth. For instance, in November 2023, The International Medical Center in Jeddah organized a two-day diabetes awareness campaign, coinciding with World Diabetes Day. The campaign focused on raising awareness of diabetes and the health risks associated with it through educating the public about the different types of diabetes, one of the most widespread diseases in the world, clarifying its root causes and the possible health complications associated with it, such as diabetic foot, diabetic retinopathy, diabetic nephropathy, dental problems, and others.

Also, in February 2023, Bayer announced the European Commission approved a label extension for Kerendia (finerenone) in the European Union (EU) to include results on cardiovascular (CV) outcomes from the Phase III FIGARO-DKD study. The study demonstrated that Kerendia reduced the risk of CV events in a broad population of patients with stages 1-4 CKD and T2D.

Restraints

Factors such as the high cost of the treatment, stringent regulatory approvals, lack of skilled professionals, lack of awareness & diagnosis, and availability of limited treatment options are expected to hamper the market.

For more details on this report - Request for Sample

Segment Analysis

The global diabetic nephropathy market is segmented based on type, treatment, end-user, and region.

The angiotensin-converting enzyme inhibitor segment accounted for approximately 54.3% of the global diabetic nephropathy market share

The angiotensin-converting enzyme inhibitor segment is expected to hold the largest market share over the forecast period. ACE inhibitors are first-line treatments for diabetic nephropathy to help manage blood pressure in those with diabetes. ACE inhibitors are a class of medications that block the activity of the angiotensin-converting enzyme, which is a key component of the renin-angiotensin-aldosterone system (RAAS). This system is heavily involved in the pathogenesis of diabetic nephropathy.

Moreover, major players more focused on clinical trials and ongoing research studies in the treatment of diabetic nephropathy would propel this market growth. For instance, in June 2023, Bayer announced the initiation of FINE-ONE, a global, multicenter, randomized, placebo-controlled, double-blind parallel-group Phase III study to evaluate the efficacy and safety of finerenone versus placebo in adults with chronic kidney disease (CKD) and type 1 diabetes (T1D). The study's primary objective is to demonstrate the superiority of finerenone over placebo in reducing urine albumin to creatinine ratio (UACR) over 6 months.

Similarly, in January 2024, a Scientific Reports research publication stated that the RENAAL study showed that the ACE inhibitor losartan reduced the risk of doubling serum creatinine, end-stage renal disease, and death by 16% compared to placebo in patients with type 2 diabetes and nephropathy.

Geographical Analysis

North America accounted for approximately 42.4% of the global diabetic nephropathy market share

North America region is expected to hold the largest market share over the forecast period rising prevalence of diabetic kidney diseases in this region, around 40% of people with diabetes could eventually develop diabetic kidney disease, (diabetic nephropathy). kidney failure leading cause in the UK- with around 20 percent of people starting dialysis in the UK.

Diabetic nephropathy is a serious complication that affects around 1 in 3 adults with diabetes in the United States. In 2023, Kidney diseases are one of the leading causes of death in the United States with approximately 37 million, or 1 in 7 Americans having chronic kidney disease (CKD). In 2023, the IDF Diabetes Atlas reported that approximately 30 to 40% of people living with diabetes develop CKD in the U.S.

Moreover, major players' presence in this region, partnerships & collaborations, and a rising number of clinical trials would drive this market growth. For instance, in May 2024, Scarborough Health Network (SHN) held an event celebrating the official launch of a new kidney disease clinic in partnership with University Health Network (UHN). SHN's Regional Nephrology Program cares for more than 6,000 patients annually and is one of Ontario's 27 Regional Multi-Care Kidney Clinics (MCKC).

Also, in November 2023, ProKidney announced positive interim data from the RMCL-002 phase 2 clinical trial of renal autologous cell therapy (REACT) for diabetic CKD. Updated positive interim Phase 2 data demonstrate REACT's potential efficacy in preserving kidney function in moderate and high-risk diabetic CKD patients.

In addition, key players' innovative launches for the treatment of diabetes nephropathy and well-established healthcare infrastructure help to propel this market growth. For instance, in December 2022, Journey Biosciences launched NaviDKD for people with diabetes to predict long-term kidney complications. NaviDKD, a biomarker-based blood test, proactively assesses the risk of kidney disease in people with diabetes years before clinical signs or symptoms appear. Along with its proprietary compass reporting platform, NaviDKD provides actionable insights for preventing and managing kidney complications before they occur.

Market Segmentation

By Type

  • Type-1 Diabetes
  • Type-2 Diabetes

By Treatment

  • Drug Class
    • Angiotensin Converting Enzyme (ACE) Inhibitor
    • Angiotensin Receptor Blockers (ARBs)
    • Diuretics
    • Calcium Channel Blockers (CCBs)
    • Renin Inhibitors
    • Others
  • Renal Replacement Therapies
    • Dialysis
    • Kidney Transplantation

By End-user

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Home Care
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

The major global players in the diabetic nephropathy market include Novartis AG, Merck & Co., Inc., Johnson & Johnson Services, Inc., Sanofi, AstraZeneca, AbbVie Inc., Eli Lilly and Company, Boehringer Ingelheim International GmbH, Bristol Myers Squibb, and GSK plc among others.

Key Developments

  • In May 2024, Novo Nordisk's (NOVOb.CO), opens a new tab Ozempic slowed the worsening of kidney dysfunction in patients with type 2 diabetes and lowered the risk of kidney failure, heart problems, stroke, and death, according to detailed results from a late-stage trial.
  • In September 2023, Boehringer Ingelheim and Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) 10 mg tablets to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death and hospitalization in adults with chronic kidney disease (CKD) at risk of progression.
  • In June 2022, Mitsubishi Tanabe Pharma Corporation announced that has acquired approval for partial changes to CANAGLU Tablets 100mg (CANAGLU) for the additional indication of chronic kidney disease complicated with type 2 diabetes mellitus.

Why Purchase the Report?

  • To visualize the global diabetic nephropathy market segmentation based on type, treatment, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of global diabetic nephropathy market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping is available in Excel consisting of key products of all the major players.

The global diabetic nephropathy market report would provide approximately 62 tables, 59 figures, and 185 Pages.

Target Audience 2024

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Treatment
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Prevalence of Diabetic Population
      • 4.1.1.2. Technological Advancements in Diagnosis Techniques
      • 4.1.1.3. Increased Clinical Studies and Government Initiatives
    • 4.1.2. Restraints
      • 4.1.2.1. The High Cost of Treatment
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Unmet Needs
  • 5.6. PESTEL Analysis
  • 5.7. Patent Analysis
  • 5.8. SWOT Analysis

6. By Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 6.1.2. Market Attractiveness Index, By Type
  • 6.2. Type-1 Diabetes*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Type-2 Diabetes

7. By Treatment

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 7.1.2. Market Attractiveness Index, By Treatment
  • 7.2. Drug Class*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Angiotensin Converting Enzyme (ACE) Inhibitor
    • 7.2.4. Angiotensin Receptor Blockers (ARBs)
    • 7.2.5. Diuretics
    • 7.2.6. Calcium Channel Blockers (CCBs)
    • 7.2.7. Renin Inhibitors
    • 7.2.8. Others
  • 7.3. Renal Replacement Therapies
    • 7.3.1. Dialysis
    • 7.3.2. Kidney Transplantation

8. By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.1.2. Market Attractiveness Index, By End-User
  • 8.2. Hospitals & Clinics *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Ambulatory Surgical Centers
  • 8.4. Home Care
  • 8.5. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. UK
      • 9.3.6.3. France
      • 9.3.6.4. Italy
      • 9.3.6.5. Spain
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Novartis AG *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio & Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Merck & Co., Inc
  • 11.3. Johnson & Johnson Services, Inc
  • 11.4. Sanofi
  • 11.5. AstraZeneca
  • 11.6. AbbVie Inc
  • 11.7. Eli Lilly and Company
  • 11.8. Boehringer Ingelheim International GmbH
  • 11.9. Bristol Myers Squibb
  • 11.10. GSK plc

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us